These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23811254)

  • 41. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
    Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger CM; Chen L; Xie F; Curtis JR; Lewis JD
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1293-1301.e5; quiz e70, e72. PubMed ID: 25724699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A; Castro J; Barreiro M; Carpio D; Pereira S; Lorenzo A
    J Crohns Colitis; 2010 Dec; 4(6):654-60. PubMed ID: 21122576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease.
    Biancheri P; Di Sabatino A; Rovedatti L; Giuffrida P; Calarota SA; Vetrano S; Vidali F; Pasini A; Danese S; Corazza GR; MacDonald TT
    Inflamm Bowel Dis; 2013 Feb; 19(2):259-64. PubMed ID: 23328772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.
    Kappelman MD; Wohl DA; Herfarth HH; Firestine AM; Adler J; Ammoury RF; Aronow JE; Bass DM; Bass JA; Benkov K; Tobi CB; Boccieri ME; Boyle BM; Brinkman WB; Cabera JM; Chun K; Colletti RB; Dodds CM; Dorsey JM; Ebach DR; Entrena E; Forrest CB; Galanko JA; Grunow JE; Gulati AS; Ivanova A; Jester TW; Kaplan JL; Kugathasan S; Kusek ME; Leibowitz IH; Linville TM; Lipstein EA; Margolis PA; Minar P; Molle-Rios Z; Moses J; Olano KK; Osaba L; Palomo PJ; Pappa H; Park KT; Pashankar DS; Pitch L; Robinson M; Samson CM; Sandberg KC; Schuchard JR; Seid M; Shelly KA; Steiner SJ; Strople JA; Sullivan JS; Tung J; Wali P; Zikry M; Weinberger M; Saeed SA; Bousvaros A
    Gastroenterology; 2023 Jul; 165(1):149-161.e7. PubMed ID: 37004887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
    Canhão H; Rodrigues AM; Mourão AF; Martins F; Santos MJ; Canas-Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araújo D; Silva C; Santos H; Duarte C; da Silva JA; Pimentel-Santos FM; Branco JC; Karlson EW; Fonseca JE; Solomon DH
    Rheumatology (Oxford); 2012 Nov; 51(11):2020-6. PubMed ID: 22843791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
    Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
    Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adalimumab safety in global clinical trials of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Panaccione R; Robinson AM; Lau W; Li J; Cardoso AT
    Inflamm Bowel Dis; 2009 Sep; 15(9):1308-19. PubMed ID: 19434735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF-α treatment for post-anastomotic ulcers and inflammatory bowel disease with Crohn's-like pathologic changes following intestinal surgery in pediatric patients.
    Freeman JJ; Rabah R; Hirschl RB; Maspons A; Meier D; Teitelbaum DH
    Pediatr Surg Int; 2015 Jan; 31(1):77-82. PubMed ID: 25348881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.